Prostate-specific membrane antigen radioguided surgery in prostate cancer: A narrative review
PSMA-RGS is feasible and safe in both primary and salvage settings. In appropriately selected patients, it may contribute to longer therapy-free survival (36 months) and prolonged biochemical recurrence-free survival (19 months).
Publication Details
- Journal
- Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication
- Published
- 2025-12-01
- DOI
- https://doi.org/10.5173/ceju.2025.0121
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00